menu

Quintiles Library

Show Filters
Presentation
As if patient identification and engagement weren’t challenging enough, add in a rare disease study, and it can feel like a daunting process. Patient populations are small and widely dispersed around the globe, and finding the proper sites to support these patients is difficult. As an emerging biopharma company, limited resources can make these challenges that much...
Explore More
Fact Sheet
Risk-based monitoring (RBM) continues to transform clinical development using data insights delivered by innovative technology, enhanced processes and new roles to optimize execution. Biopharma is adopting RBM as the standard execution model for their studies. QuintilesIMS is leading this evolution with an expanded RBM offering, Centralized Monitoring. Learn more about...
Read More
Presentation
Effective patient engagement and empowerment – patients’ involvement in their own healthcare and decision-making – is of vital importance. Why? Because it has the potential to improve treatment adherence, health outcomes and patient quality of life. Peter Rutherford will explore the importance of patient engagement and the impact on health outcomes; Chris Kelly will...
Explore More
White Paper
Early clinical development (ECD) studies have become increasingly complex and expensive in recent years. One approach to address this is the use of a site network model to ensure we are utilizing the geography and site best suited for a particular study and therapeutic area. This approach allows a blending of timelines, cost, experience, and quality to ensure the best...
Explore More
Video
QuintilesIMS provides deep experience for superior delivery of your Phase I trial to help you drive healthcare forward. Your early clinical development is critical to the success of getting your molecule to market. Named the leader in Phase I studies for five consecutive years, QuintilesIMS provides deep experience in conducting first-in-human or healthy volunteer...
Fact Sheet
Improving patient safety is our #1 priority. When you partner with QuintilesIMS, our experienced cross-functional teams will deliver comprehensive and innovative patient safety solutions across your product’s lifecycle – from clinical through post-approval.  For information on our pharmacovigilance services, please click here.
Read More
Fact Sheet
Regenerative medicine is transitioning from the lab to the clinic and facing a shifting regulatory landscape, constrained clinical manufacturing capacity, and limited sites with stem cell clinical trial experience. Working with California Institute for Regenerative Medicine (CIRM) and its Alpha Stem Cell Clinics, the Stem Cell Center plays a role in providing guidance...
Read More
Fact Sheet
The market access challenge requires a successful response to multiple stakeholders from different countries – each with their own needs and requirements. Anticipating these diverse demands and developing the necessary evidence requires a nuanced understanding of the dynamic payer environments you must navigate. QuintilesIMS’s HTA Accelerator offers an integrated solution...
Read More
Fact Sheet
Overcoming the complexities of the different European markets can be a daunting exercise. Between achieving a rapid launch, satisfying internal and external stakeholders and achieving an optimal reimbursement price, you may need an expert to provide you the right advice to help you accomplish your strategic goals. Obtain knowledge of pricing and reimbursement as well as...
Read More
Fact Sheet
At QuintilesIMS we have developed a simple, beautiful forecasting platform built just for life sciences. It has all the complex features needed for this industry out of the box, meaning you can build forecasts in fewer clicks with less time. And, it can be customized to work for your needs – from very simple forecasts to complex, multisegment, patient-flow models. Our...
Read More
Article
Specialised, field-based Medical Affairs services can enable effective, compliant therapeutic area and product understanding prior to launch to help facilitate and sustain optimal patient access to medicines. In an environment where clear, transparent and compliant communication is increasingly required, Medical Science Liaisons (MSLs) provide a credible link to external...
Explore More
Article
Life sciences companies spend an average of $300,000 to recruit each participant for a Phase III clinical trial. However, despite this investment, 80% of trials fail to meet their initial patient enrolment quotas. Challenges associated with the identification of subjects to participate in a study can cause serious bottlenecks and delay study completion, slowing...
Explore More
Article
The aim of medical care is to improve survival and quality of life for patients. Those with long-term and life-limiting conditions have particular needs due to the progressive and/or long-term nature of the underlying pathophysiology. However, it is now clear that patients who are engaged in their own health and treatment may have better outcomes. Biopharma companies...
Explore More
Fact Sheet
As your products age, the pressure to minimize costs and grow revenue continues to increase. To effectively manage your portfolio, you need to do more than simply meet regulatory requirements. By aligning all aspects of Marketed Product Maintenance, QuintilesIMS can help you maximize value, ensure regulatory compliance and centralize safety oversight. It is what we call...
Read More
Video
QuintilesIMS offers you the personalized attention and global therapeutic expertise that will help you confidently create the right evidence and optimize the value of your asset. Combine your knowledge and innovation with a confidence that comes from having the experience and insight of QuintilesIMS on your side. QuintilesIMS and Emerging Biopharma – the credibility of...
White Paper
Antibody-drug conjugates (ADCs), which now account for approximately 20% of the clinical pipeline of antibodies for cancer, are comprised of three components: a monoclonal antibody chosen to target a specific receptor, a potent cytotoxic agent, and a linker that connects (conjugates) the antibody to the cytotoxin. From an efficacy perspective, there is substantial...
Explore More
Fact Sheet
Keeping track – and making sense – of all of the information required by regulatory authorities is more complex than ever. Our teams and technology can handle it all with our Regulatory Information Management (RIM) solution. Combining real-time intelligence and a leading-edge publishing platform with expert regulatory teams, we can optimize your submissions and marketed...
Read More
Fact Sheet
Establishing an effective Quality Management System is an essential requirement for any manufacturer that designs, produces or distributes pharmaceutical or medical device products.
Read More
Scientific Poster
BRCA1 and BRCA2 are genes expressed in cells of the breast and other tissues. These genes are involved in both familial breast cancer and ovarian cancers. BRCA 1/2 produce tumor suppressor proteins which regulate the repair of damaged DNA, mutations within these genes can affect the stability of the cells genetic material1. As a result, cells are more likely to develop...
Explore More
Fact Sheet
Data integrity – maintaining and assuring the accuracy and consistency of data over its entire life-cycle – is critically important in the biopharma industry. First and foremost, public health must be protected. Breaches in data integrity can also interrupt product supply, depriving patients of needed treatments and posing a threat to business. Unlike many other...
Read More